Acurx Pharma Raises $2.5M via Direct Offering

Acurx Pharmaceuticals, Inc. entered into a Securities Purchase Agreement on April 15, 2026, for a registered direct offering. The company agreed to sell 816,068 shares of common stock at $3.03 per share and pre-funded common stock purchase warrants for up to 9,017 shares at $3.029 per share. This offering is expected to generate approximately $2.5 million in gross proceeds, which will be used for working capital and other general corporate purposes.